Connect with us

Press Release

China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia

Published

2 days ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the “Authorization Term”). Upon the expiration of the Authorization Term, it may be automatically renewed for an additional ten years, subject to specific conditions stipulated in the Agreement.

 

ABP-671 is a class 1 innovative chemotherapeutic drug for the treatment of gout and hyperuricemia, currently in Phase 2b/3 clinical trials for gout in China and overseas. The Product reduces renal re-absorption of uric acid by inhibiting Urate Anion Transporter 1 (URAT1). The results of two completed phase 2 clinical trials demonstrated favorable efficacy and safety profiles across multiple dose groups (ranging from 1 mg to 12 mg) of ABP-671. The 2 mg once-daily dosage of the Product was proved to be as effective as, or even better than, benzbromarone or febuxostat (maximum dosage of 80mg). The reduction in uric acid levels was sustained throughout the 24-hour period, with no significant safety concerns identified. This product is anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia[1]. Multiple patents in regard to substance and use of the ABP-671 have been granted in China.

 

Hyperuricemia is defined as a fasting blood uric acid level exceeding 420μmol/L (7.0 mg/dL) in adults on a normal purine diet on two separate days. The deposition of urate crystals in hyperuricemia patient results in arthritis, medically termed gout. Hyperuricemia and gout can cause acute and chronic inflammatory injury in articular cartilage, bone, kidney and vascular wall, which can lead to multiple organ damage of the heart, brain and kidney, etc. The data presented in the White Paper on Hyperuric Acid and Gout Trends in China (2021) indicates that, the incidence rate of hyperuricemia is 13.3%, with approximately 177 million hyperuricemia patients and the incidence rate of gout is 1.1% in general, with about 14.66 million gout patients in China. Frost & Sullivan indicates that, the number of people with hyperuricemia and gout in China will continue to increase in the future, reaching 240 million and 52.2 million respectively by 2030. Currently, the commonly used uric acid-lowering drugs in clinical practice in China are those which inhibit uric acid synthesis or promote uric acid excretion. Due to certain limitations in the efficacy and safety of the marketed uric acid-lowering drugs, such as causing renal failure, sudden cardiac death or severe liver toxicity. There is still an urgent need for effective and safe uric acid-lowering drugs among gout and hyperuricemia patients in China.

 

ABP-671 is currently with the potential to be the promising and safe product for the treatment of gout and hyperuricemia. Through this collaboration, it fills the blank in the CMS’s product portfolio of the treatment of gout. Gout and hyperuricemia are both rheumatic diseases and chronic metabolic diseases, which are highly consistent with the Group’s strategic layout in the cardio-cerebrovascular/ gastroenterology business and the network resources of marketed products. If approved for marketing in the future, the Product will synergize with the Group’s marketed product Metoject (methotrexate injection) in rheumatology and with Elcitonin (elcatonin injection) in endocrinology and orthopedics, in terms of expert network and market resources. Based on the unmet clinical needs and the expected solid clinical data of the Product, the Group is looking forward to the smooth advancement of the clinical development of ABP-671, allowing patients with relevant indications to benefit from this innovative treatment sooner.

 

About ATOM THERAPEUTICS

Atom Therapeutics was founded in March 2012, focused on the research and development of innovative drugs with global commercial value and competitiveness in the metabolic and inflammatory area. Atom Therapeutics’s main core team members come from the United States, with extensive experience in the research and development of innovative drugs. Atom Therapeutics has achieved remarkable development in the past few years. Atom Therapeutics’s core product ABP-671 is under pivotal clinical stage for the treatment of chronic gout. Atom Therapeutics’s another small molecule innovative drug named as ABP-745, used for indications in the field of anti-inflammatory immune indications. The Phase 1 clinical of ABP-745 exhibited outstanding pharmacokinetics and safety. The clinical trial is on the verge of entering Phase 2. For more information about Atom Therapeutics and its pipeline, please visit https://www.atombp.com/.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference:

  1. The results of Phase 2 clinical trials was published and can be found at: https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

LTR Taxis Unveils Premium Airport Taxi Transfer Services in London

Published

57 minutes ago

on

December 4, 2024

By

London, United Kingdom, 4th Dec 2024 — LTR Taxis, a leading name in the transportation industry, proudly announces the launch of its premium airport taxi transfer services in London. Designed to provide passengers with unparalleled comfort, reliability, and convenience, this new offering promises to redefine the airport transfer experience for leisure and business travelers.

With London serving as a bustling gateway for millions of travelers each year, the need for efficient and luxurious airport transfer services has never been greater. LTR Taxis rises to this demand with a service that combines modern technology, exceptional customer care, and a fleet of premium vehicles.

A Commitment to Excellence

LTR Taxis has built its reputation on delivering top-tier transportation solutions, and its premium airport taxi transfer service is no exception. This new venture reflects the company’s dedication to meeting the evolving needs of travelers while maintaining the highest standards of service.

“Our goal is to provide more than just a ride—we want to offer an experience,” said PR Manager at LTR Taxis. “Whether you’re traveling for business or pleasure, our premium airport transfer services ensure that your journey starts and ends on a high note.”

Key Features of LTR Taxis’ Premium Airport Transfer Services

1- Luxury Vehicles

LTR Taxis’ fleet includes various high-end vehicles that cater to diverse preferences. From executive sedans to spacious SUVs and minibusses, passengers can choose a vehicle that suits their requirements. Each car is equipped with modern amenities, including: 

  • Plush leather seating
  • Complimentary Wi-Fi
  • Bottled water
  • Climate control for ultimate comfort

2- Professional Chauffeurs

Every LTR Taxis chauffeur is highly trained, fully licensed, and committed to exceptional service. With in-depth knowledge of London and its surrounding areas, drivers ensure a smooth and efficient journey, regardless of traffic or time constraints.

3- 24/7 Availability

Understanding the unpredictability of travel schedules, LTR Taxis operates round-the-clock to accommodate flights at any hour. Whether arriving late at night or departing early in the morning, a reliable transfer is always just a booking away.

4- Real-Time Flight Monitoring

To ensure seamless pickups, LTR Taxis integrates advanced flight tracking technology. This allows the team to monitor flight schedules in real time and adjust pickup times in case of delays or early arrivals.

5- Transparent Pricing

LTR Taxis takes pride in offering fixed and transparent pricing. Customers can confidently book, knowing there are no hidden charges or unexpected fees, even during peak travel.

Serving London’s Major Airports

LTR Taxis’ premium airport transfer services are available across all major London airports, including:

  • Heathrow Airport
  • Gatwick Airport
  • Stansted Airport
  • Luton Airport
  • London City Airport

The company also facilitates inter-airport transfers for passengers with connecting flights, ensuring a hassle-free travel experience.

A Tailored Experience for Every Traveler

LTR Taxis understands that every traveler has unique needs. Whether you’re a solo traveler, a family with children, or a corporate group, the service is designed to be flexible and accommodating.

  • Corporate Travelers: Business clients can enjoy a discreet and efficient transfer experience with onboard Wi-Fi and spacious interiors to stay productive.
  • Families: LTR Taxis offers child-friendly services, including car seats upon request, making family travel safer and more convenient.
  • Tourists: Visitors can rely on friendly chauffeurs who are well-versed in London’s iconic landmarks and hidden gems, turning a straightforward transfer into an informative journey.

Booking Made Easy

LTR Taxis has simplified the booking process to ensure a seamless experience:

  • Online Platform: Users can book directly through the company’s user-friendly website, where they can input travel details, select vehicles, and receive instant confirmation.
  • Mobile App: A dedicated app provides added convenience, allowing passengers to manage bookings, track drivers in real time, and access 24/7 customer support.
  • Phone Reservations: For those who prefer personalized assistance, LTR Taxis’ support team is available by phone to guide customers through the booking process.

Focus on Sustainability

In addition to providing luxury and reliability, LTR Taxis is committed to environmental sustainability. The company has invested in eco-friendly vehicles, including hybrid and electric options, to reduce its carbon footprint. Passengers can now choose a green travel option without compromising quality or comfort.

“We believe in responsible business practices,” added Steve, PR Manager at LTR Taxis. “By integrating sustainable vehicles into our fleet, we’re contributing to a cleaner, greener future while continuing to deliver exceptional service.”

Special Introductory Offer

LTR Taxis is offering a limited-time discount for first-time users of their premium airport taxi transfer service to celebrate the launch. Passengers can enjoy up to 20% off their first booking.

About LTR Taxis

LTR Taxis is a trusted provider of transportation services renowned for its commitment to quality, reliability, and customer satisfaction. With years of experience and a team of dedicated professionals, the company continues to set new benchmarks in the industry. We Offer Heathrow Airport Taxi, Gatwick Airport Taxi, Luton Airport Taxi, Stansted Airport Taxi and London City Airport taxi

The introduction of premium airport taxi transfers marks a significant milestone in LTR Taxis’ journey, further solidifying its position as a leader in the market.

Media Contact

Organization: LTR Taxis

Contact Person: LTR Taxis

Website: https://ltrtaxis.com/

Email: ltrtaxistransfer@gmail.com

Address: 90 Hoxton Street, London, Greater London England, N1 6LP

City: London

Country: United Kingdom

Release Id: 04122420883

The post LTR Taxis Unveils Premium Airport Taxi Transfer Services in London appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Dunbrook Associates Unveils Tailored Investment Strategies for Every Life Stage

Published

57 minutes ago

on

December 4, 2024

By

Ontario, Canada, 4th Dec 2024 – Dunbrook Associates, a leading financial advisory firm in Canada, introduces comprehensive investment strategies designed to evolve with life’s changing milestones. From building a foundation in early adulthood to managing wealth in retirement, these tailored approaches aim to support individuals in achieving financial security and long-term growth.  

Each phase of life presents unique financial challenges and opportunities. In the early years, the focus is on maximizing growth potential and establishing solid financial habits. Strategies such as investing in growth-focused assets like stocks and ETFs, leveraging low-cost options like index funds, and contributing to employer-sponsored retirement plans are central to building a strong financial base. Additionally, maintaining an emergency fund ensures readiness for unexpected expenses.  

In the middle years, as financial stability increases, diversification becomes paramount. Expanding portfolios to include bonds, real estate, and alternative investments helps balance risk and reward. Planning for major life expenses, such as children’s education or homeownership, can be supported through tax-advantaged accounts like 529 plans. A steady increase in retirement contributions further solidifies long-term goals during this stage.  

Approaching retirement, the focus shifts to protecting accumulated wealth and maximizing savings. Adjusting asset allocations to include more stable investments, such as bonds, helps mitigate market volatility while maintaining some exposure to equities for continued growth. This period is also an ideal time to review estate plans and reduce debt to ensure a secure financial future.  

In retirement, strategic wealth management takes center stage. Emphasis on income-generating investments, including annuities and dividend-paying stocks, provides a steady stream of funds to cover living expenses. A balanced portfolio ensures purchasing power is preserved against inflation, while dedicated savings address healthcare costs and long-term care needs. Thoughtful withdrawal strategies help retirees sustain their resources throughout their golden years.  

Throughout all life stages, certain principles remain universal. Starting early to take advantage of compounding growth, regularly reviewing financial plans, avoiding emotional decision-making, and seeking expert advice form the backbone of successful investment strategies.  

Dunbrook Associates prides itself on offering personalized financial plans that adapt to each client’s evolving needs. With a deep understanding of the complexities of modern financial planning, the firm delivers solutions that prioritize long-term success and financial well-being.

About Dunbrook Associates

Dunbrook Associates is a leading Canadian financial advisory firm committed to providing personalized investment strategies that evolve with clients’ life stages. With expertise in navigating the complexities of financial planning, they offer tailored solutions to help individuals build wealth, protect assets, and achieve long-term financial security. Dunbrook Associates prioritizes clients’ unique needs, delivering expert guidance to ensure a prosperous future at every phase of life.

For more information about tailored investment strategies and professional financial guidance, visit https://dunbrook.ca 

Media Contact

Organization: Dunbrook Associates

Contact Person: Tianna Hackett

Website: https://dunbrook.ca

Email: admin@dunbrook.ca

City: Ontario

Country: Canada

Release Id: 04122420867

The post Dunbrook Associates Unveils Tailored Investment Strategies for Every Life Stage appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Baby XRP Announces the Launch of $BABYXRP Token on Solana Blockchain

Published

2 hours ago

on

December 4, 2024

By

PR Byline:

$BABYXRP aims to give crypto enthusiasts who missed the crypto wave a second chance. 

Baby XRP  has announced the launch of its official token $BABYXRP on the Solana blockchain with the goal enhance accessibility and inclusivity in the cryptocurrency ecosystem.  Combining blockchain technology with the humor and creativity of meme culture, Baby XRP draws inspiration from the success of XRP. It provides both experienced crypto users and newcomers an opportunity to engage with an active community and explore the growing cryptocurrency ecosystem while enjoying a community-driven experience.

Baby XRP stands out not just for its playful branding but for its mission to unite laughter, community engagement, and cutting-edge blockchain technology. Hosted on the Solana blockchain, Baby XRP benefits from Solana’s renowned speed and efficiency, ensuring smooth transactions and scalability for its growing user base.

The creators of Baby XRP are determined to build a community-driven token that goes beyond the standard meme coin formula. Their approach emphasizes the importance of fostering connections among members, promoting inclusivity, and inspiring creativity. “We’re more than a coin; we’re a movement built on fun, memes, and the power of community,” a spokesperson for Baby XRP stated.

A key feature of Baby XRP is its zero-tax policy, enabling seamless trading without additional fees. The token’s launch features a supply of 1 billion $BABYXRP coins, all of which are in circulation, with liquidity provider (LP) tokens already burned to ensure stability and trust within the ecosystem.

Baby XRP’s success hinges on its engaged community, where members are encouraged to create and share memes, interact on social media, and participate in various campaigns and giveaways. The project’s commitment to inclusivity and fun has already started to attract a vibrant following.

The acquisition of Baby XRP is designed to be straightforward and accessible. Newcomers to cryptocurrency can follow a simple step-by-step process to purchase $BABYXRP. It begins with creating a wallet using the Phantom app, acquiring Solana (SOL), and connecting to Raydium, a decentralized exchange. From there, users can swap SOL for Baby XRP tokens effortlessly.

This streamlined approach reflects the creators’ commitment to onboarding users from all levels of crypto expertise. By eliminating entry barriers and taxes, Baby XRP positions itself as a token for everyone.

Baby XRP seeks to redefine what a meme coin can achieve, leveraging the rapid processing speeds of Solana’s blockchain to create a seamless user experience. Its unique value proposition lies in merging the utility of XRP-inspired innovation with the cultural phenomenon of meme tokens, offering a hybrid that is both entertaining and practical.

The project is already gaining momentum through its active presence on platforms like X (formerly Twitter) and Telegram, where the Baby XRP community gathers to exchange ideas, memes, and updates. The developers invite all crypto enthusiasts to join the movement and contribute to the growing ecosystem.

Baby XRP represents a new era of cryptocurrency—one where fun and utility coexist. Whether it’s through engaging memes, zero-tax trades, or an inclusive community spirit, Baby XRP is determined to leave its mark on the digital asset landscape.

For more information about Baby XRP, visit its official website at babyxrp.xyz. 

Contract

2QYmQA5k8dFei18MjoaHocEzStBohFiifdnK2vi2pump

For updates, follow Baby XRP on X at @BabyRippleXRP, or join the conversation on Telegram at BabyRippleXRP.

Media Contact

Company name: Baby XRP

Contact person: Dave Aston

Website: https://babyxrp.xyz

Email: contact@babyxrp.xyz

City: London

Country: England

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us